Coronavirus vaccine: ZyCoV-D is a three-dose vaccine given intradermally using a painless, needle-free PharmaJet system, Tropis, on days 0, 28, and 56.
Pharmaceutical company Zydus announced on Wednesday that it has started shipping its COVID-19 ZyCoV-D vaccine to the Government of India against their order from its recently commissioned state-of-the-art Zydus Vaccine Technology Center of Excellence at Zydus Biotech. Park in Changodar, Ahmedabad.
The company also plans to make the vaccine available on the private market.
The vaccine will cost £265 per dose, and the applicator will be offered for £93 per dose, excluding VAT.
Zydus Cadila’s Covid Vaccine ZyCoV-D To Be Used In 7 States Initially
Zydus VTEC manufactures the drug substance for a needle-free DNA plasmid ZyCoV-D vaccine. The production progression and the movement of materials during the production process at the plant are automated.
Zydus has also agreed with Shilpa Medicare Limited, a contract manufacturing organization, to produce mutually acceptable doses of ZyCoV-D.
The company also agreed with Enzychem Lifesciences of the Republic of Korea to obtain a license to manufacture and transfer plasmid DNA vaccine technology.
ZyCoV-D: NEW needle-free vaccine against Coronavirus
Ahmedabad-based vaccine maker Zydus Cadila announced on Wednesday that it had started supplying the center with the Covid ZyCoV-D vaccine.
“The company has commenced deliveries of its Covid-19 ZyCoV-D vaccine to the Government of India on their order from its recently commissioned state-of-the-art Zydus Vaccine Technology Center of Excellence at Zydus Biotechnology Park in Ahmedabad,” Zydus said in a statement.
He also added that the vaccine would be available on the private market.
ZyCoV-D is a three-dose vaccine administered intradermally using a painless, needle-free PharmaJet system on days 0, 28, and 56. It will cost Rs 265 per dose, and the applicator will be offered at Rs 93 per dose, exclusive of VAT.
Central Drug Regulator Approves Shelf Life Of COVID-19 Vaccines CoviShield, Covaxin, ZyCoV-D
“The national regulatory body, i.e., CDSO, has approved a shelf life of nine months for the Covishield vaccine, 12 months for the Covaxin vaccine, and six months for the ZyCoV-D vaccines from the date of manufacture,” Health Minister Mansoukh Mandavia said.
New Delhi: The Central Medicines Standards Organization (CDSO) has approved a shelf life of up to 12 months for the covid-19 vaccines Covaxin, up to nine months for Covishield, and up to six months for ZyCoV-D vaccines, the Lok Sabha said. Friday.
Regarding introducing booster doses, Union Health Minister Mansukh Mandavia said that the National Immunization Technical Advisory Group (NTAGI) and the National COVID-19 Vaccine Administration Panel (NEGGVAC) are discussing and reviewing scientific data related to this aspect.
When asked about the expiration date of the nationally approved Covid vaccines and their period of activity in vaccinated persons, Mr. Mandavia wrote that the vaccines were only recently developed, so there is no scientific data on the duration of protection. Still developing globally.
Zydus Cadila’s ZyCoV-D To Be Introduced In Covid Vaccine Drive Shortly: Centre
“The national regulatory body, i.e., CDSO, has approved a shelf life of nine months for the Covishield vaccine, 12 months for the Covaxin vaccine, and six months for the ZyCoV-D vaccines from the date of manufacture,” said Mandavia.
Mr. Mandavia said the central government is closely monitoring state and union territory covid-19 vaccine inventories on whether the government has stockpiled unused vaccines in public and private hospitals and proposes procuring and redistributing unused vaccines before the expiry date. Their suitability and ensure their optimal use.
Stocks of unused Covid-19 vaccines in private hospitals nearing their expiry date have been handed over for redistribution by respective state governments on the advice of the Union government for their timely use, he said.
Listing the actions taken by the government to ensure proper production and delivery of Covid vaccines and booster doses, as well as the total costs and funds allocated and disbursed in this regard, Mr. Research assistance to the biotechnology industry. Council (BIRAC), PSU of the Department of Biotechnology, efforts have been made to strengthen the capacity of the Indian COVID-19 vaccine industry to ensure optimal vaccine production.
In this regard, the expansion of production capacity was supported by Bharat Biotech International Limited (BBIL) and Indian Immunologicals Limited (IIL), Hyderabad.
ZyCoV-D: NEW needle-free vaccine against Coronavirus
The mission-backed IIL has reached a production capacity of about 20 lakh monthly doses equivalent to the drug substance (DS) of Covaxin.
Verification of the BBIL facility at Malur, Bangalore, has been completed, and DS production commenced in August 2021. Additionally, facility expansion support at Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL), Bulandshahr; and Haffkine Biopharmaceutical Corporation Ltd (HBPCL), Mumbai; for the production of Covaxin is being considered.
According to Mr. Mandavia, has been allocated £260 crore to support the facility’s modernization to increase production of Covaxin, of which £27.25 crore has been disbursed so far.
In addition, DBT, along with PSU BIRAC, is facilitating expert advisory support for the upgradation of the Gujarat COVID Vaccine Consortium (GCVC) facility for expanded production of Covaxin, he said in a written reply.
In the current financial year, i.e., 2021-2022, £35,000 crores have been allocated for implementing the COVID-19 vaccination program.